Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Rating of “Moderate Buy” from Analysts

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been given a consensus rating of “Moderate Buy” by the twenty-three research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have covered the stock in the last year is $1,074.95.

Several equities research analysts recently weighed in on REGN shares. Morgan Stanley dropped their price objective on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Bank of America raised their price target on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. TD Cowen raised their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday. Royal Bank of Canada restated an “outperform” rating and issued a $1,229.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, June 24th. Finally, Truist Financial restated a “buy” rating and issued a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd.

Regeneron Pharmaceuticals Price Performance

REGN opened at $1,078.63 on Monday. The firm has a market cap of $118.85 billion, a price-to-earnings ratio of 31.87, a price-to-earnings-growth ratio of 2.20 and a beta of 0.13. Regeneron Pharmaceuticals has a fifty-two week low of $723.56 and a fifty-two week high of $1,106.16. The company’s 50-day moving average price is $1,033.85 and its 200 day moving average price is $976.79. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). The business had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. As a group, sell-side analysts expect that Regeneron Pharmaceuticals will post 37.02 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Marion Mccourt sold 1,137 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the transaction, the executive vice president now owns 12,931 shares of the company’s stock, valued at approximately $13,540,179.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Marion Mccourt sold 1,137 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the transaction, the executive vice president now owns 12,931 shares of the company’s stock, valued at approximately $13,540,179.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph J. Larosa sold 1,866 shares of the firm’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the completion of the transaction, the executive vice president now directly owns 37,937 shares of the company’s stock, valued at approximately $41,311,496.15. The disclosure for this sale can be found here. In the last 90 days, insiders sold 65,074 shares of company stock valued at $64,546,123. Company insiders own 7.48% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. West Paces Advisors Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 23 shares during the period. Crewe Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $28,000. Lynx Investment Advisory acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $33,000. Family Firm Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $33,000. Finally, MCF Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 12 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.